MedTrace Logo

A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment

NCT00000902 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 217

Last updated 2021-10-29

No results posted yet for this study

Summary

The purpose of this study is to determine the value of changing anti-HIV medications in children with progressive HIV disease who have received previous treatment.

Plasma viral load (the level of HIV in the blood) is probably most effectively reduced by giving patients anti-HIV drugs which affect the virus at various stages of development. Changing the medications may enhance the results of treatment.

Conditions

  • HIV Infections

Interventions

DRUG

Ritonavir

DRUG

Nelfinavir mesylate

DRUG

Nevirapine

DRUG

Lamivudine

DRUG

Stavudine

DRUG

Zidovudine

DRUG

Zalcitabine

DRUG

Didanosine

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Andrea Kovacs

  • Sandra Burchett

Study Design

Purpose
TREATMENT

Eligibility

Min Age
6 Months
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Completion
2002-04-30

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000902 on ClinicalTrials.gov